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Abstract
As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) 
invited the manufacturer (AstraZeneca) of durvalumab  (IMFINZITM) to submit evidence for the clinical and cost effective-
ness of durvalumab for the treatment of patients with locally advanced, unresectable, stage III non-small cell lung cancer 
whose tumours express programmed death-ligand 1 (PD-L1) on ≥ 1% of tumour cells and whose disease has not progressed 
after platinum-based chemoradiation therapy. Kleijnen Systematic Reviews Ltd, in collaboration with Maastricht University 
Medical Centre, was commissioned to act as the independent Evidence Review Group (ERG). This paper summarises the 
company submission (CS), presents the ERG’s critical review on the clinical- and cost-effectiveness evidence in the CS, 
highlights the key methodological considerations, and describes the development of the NICE guidance by the Appraisal 
Committee. The CS included a systematic review that identified one randomised controlled trial, comparing durvalumab 
with SoC. Participants with tumours expressing PD-L1 on ≥ 1% of tumour cells accounted for approximately 40% of the total 
participants. In this subgroup, a benefit in progression-free survival (PFS) [hazard ratio (HR) 0.44, 95% confidence interval 
(CI) 0.31–0.63] and overall survival (HR 0.54, 95% CI 0.35–0.81) was reported. Adverse events were comparable between 
both treatments, but more serious adverse events were reported for durvalumab (64/213 [30%] vs. 18/90 [20%]). The ERG’s 
concerns regarding the economic analysis included a likely overestimation of PFS for the durvalumab arm, the choice of 
timepoint for treatment waning, as well as the way treatment waning was incorporated in the model, and potential overesti-
mation of utility values without applying an age- or treatment-related decrement. The revised ERG base-case resulted in a 
deterministic incremental cost-effectiveness ratio of £50,238 per quality-adjusted life-year gained, with substantial remaining 
uncertainty. NICE recommended durvalumab as an option for use within the Cancer Drugs Fund only in a subpopulation 
(concurrent platinum-based chemoradiation therapy) with a commercially managed access agreement in place.
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1 Introduction
Durvalumab (trade name  IMFINZITM) was appraised within 
the National Institute for Health and Care Excellence (NICE) 
single technology appraisal (STA) process. Health technolo-
gies must be shown to be clinically effective and to repre-
sent a cost-effective use of National Health Service (NHS) 
resources in order to be recommended by NICE. Within the 
STA process, the company (AstraZeneca) provided NICE 
with a written submission and a mathematical health eco-
nomic model, summarising the company’s estimates of the 
clinical- and cost-effectiveness of durvalumab for the treat-
ment of locally advanced, unresectable, stage III non-small 
cell lung cancer (NSCLC) in adults whose tumours express 
programmed death-ligand 1 (PD-L1) on ≥ 1% of tumour cells 
and whose disease has not progressed after platinum-based 
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Key Points for Decision Makers 
There is uncertainty regarding the generalisability of the 
trial data to the UK setting, and generalisability issues 
should be a key consideration in National Institute for 
Health and Care Excellence decision making.
The use of interim analyses may result in assump-
tions regarding longer-term effectiveness and treatment 
waning, for which there is currently a lack of guidance, 
thereby causing increased uncertainty and the risk of 
biased estimates.
When a trial that can provide answers to the most press-
ing questions is still ongoing and there is doubt over the 
cost effectiveness of a new technology, reimbursement 
within the Cancer Drugs Fund should be carefully con-
sidered and the value of further data collection should be 
formally assessed.
the population was narrower, i.e. only included patients in 
the relevant population whose tumours expressed PD-L1 
[1]. The intervention (durvalumab 10 mg/kg every 2 weeks 
intravenously), comparator (standard of care [SoC]) and out-
comes are defined in line with the NICE scope [1].
3  Independent Evidence Review Group 
(ERG) Review
The ERG reviewed the clinical- and cost-effectiveness 
evidence of durvalumab for this indication. As part of the 
STA process, the ERG and NICE had the opportunity to ask 
for clarification on specific issues in the CS, in response 
to which the company provided additional information [1]. 
The ERG also produced an ERG base-case to assess the 
impact of alternative assumptions and parameter values on 
the model results, by modifying the health economic model 
submitted by the company. Sections 3.1–3.6 summarise the 
evidence presented in the CS, as well as the review of the 
ERG.
3.1  Clinical Effectiveness Evidence Submitted 
by the Company
The CS reported a systematic review (SR) of the evidence 
for durvalumab for the treatment of locally advanced, unre-
sectable, stage III NSCLC in adults whose tumours express 
PD-L1 on ≥ 1% of tumour cells and whose disease has not 
progressed after platinum-based CRT. The SR identified 
one randomised controlled trial (RCT), PACIFIC, which 
compared durvalumab with SoC in adults in the population 
defined in the decision problem [2]. The population of par-
ticipants receiving durvalumab represented approximately 
67% of the overall population included in PACIFIC.
The CS reported a progression-free survival (PFS) ben-
efit with durvalumab (median 23.9 months) when com-
pared with placebo (median 5.6 months) in the PD-L1 ≥ 1% 
expression group (hazard ratio [HR] 0.44, 95% confidence 
interval [CI] 0.31–0.63). Patients in the PD-L1 ≥ 1% expres-
sion groups receiving durvalumab also observed an overall 
survival (OS) benefit (HR 0.54, 95% CI 0.35–0.81).
Common adverse events (AEs) were reported in both the 
durvalumab and placebo groups. The common AEs in the 
durvalumab patients included cough, fatigue, and radiation 
pneumonitis, whereas patients in the placebo group also 
included dyspnoea. While any AEs are comparable between 
durvalumab (205/213, 96.2%) and placebo (83/90, 92.2%), 
more serious AEs were reported for durvalumab (64/213 
[30%] vs. 18/90 [20%]).
chemoradiation therapy. This company submission (CS) was 
reviewed by an Evidence Review Group (ERG) independ-
ent of NICE [1]. The ERG, Kleijnen Systematic Reviews 
in collaboration with Maastricht University Medical Cen-
tre, produced an ERG report [1]. After consideration of the 
evidence submitted by the company, and the ERG report, 
the NICE Appraisal Committee (AC) issued guidance on 
whether or not to recommend the technology by means of 
the Final Appraisal Determination (FAD), which is open for 
appeal. This paper presents a summary of the ERG report 
and the development of the NICE guidance. Furthermore, it 
highlights important methodological issues that were identi-
fied which may help in future decision making.
Full details of all relevant appraisal documents (includ-
ing the appraisal scope, CS, ERG report, consultee submis-
sions, appraisal consultation document [ACD], FAD, and 
comments from consultees) can be found on the NICE web-
site [1].
2  The Decision Problem
The CS defined the population as “adults with locally 
advanced, unresectable, stage III NSCLC whose tumours 
express programmed death-ligand 1 (PD-L1) on ≥ 1% of 
tumour cells (TCs) and whose disease has not progressed 
following platinum-based chemoradiation therapy (CRT)” 
[1]. In the CS, the company emphasises the prevalence of 
lung cancer as being the third most common cancer in the 
UK. Lung cancer was identified as being the main cause of 
cancer-related death [1]. Compared with the NICE scope, 
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3.2  Critique of Clinical Effectiveness Evidence 
and Interpretation
As previously highlighted, the decision problem used in 
the CS was narrower than the NICE scope. Participants in 
the relevant subgroup (tumour expressing PD-L1 on ≥ 1% 
of tumour cells) accounted for approximately 40% of the 
total participants in the PACIFIC trial; however, the ran-
domisation was not stratified based on PD-L1 status. While 
reported baseline characteristics such as age, histology or 
smoking status were balanced between the durvalumab and 
placebo groups, there were potential problems linked to 
overinterpretation of subgroup analyses that might impact 
on the findings.
The ERG was concerned about the applicability of dur-
valumab to a population receiving different types of CRT 
cycles. The CS notes that in the PACIFIC trial, concurrent 
CRT was received prior to beginning treatment with dur-
valumab. However, the clinical expert highlighted that “most 
UK patients receive sequential rather than overlapping treat-
ment”, while “the efficacy and safety of durvalumab in the 
PACIFIC study was evaluated after overlapping, rather than 
sequential, CRT”. The response to a request for clarification 
suggested the cohort in the PACIFIC trial is generalisable 
to UK patients with locally advanced, unresectable, stage 
III NSCLC, and that survival rates might be lower among 
patients treated with sequential CRT approaches than over-
lapping approaches. However, as stated in the response, 
the effectiveness of durvalumab in following sequential 
therapy remains unknown, i.e. “… clinicians would expect 
to see some benefit of durvalumab treatment after sequen-
tial CRT, although the magnitude of this remains uncertain 
in the absence of robust clinical evidence”. These issues 
impacted on the certainty regarding the findings and might 
limit the applicability to UK clinical practice. Furthermore, 
the PACIFIC trial included only eight patients from the UK.
Efficacy results came from an interim cut-off in 
March 2018, i.e. not from the final analysis, which was 
planned at a ‘maturity’ of 70%, i.e. when 70% of patients 
had died. At the cut-off, the percentage of patients who had 
died was reported to be 33% in the durvalumab group and 
49.5% in the placebo group.
3.3  Cost‑Effectiveness Evidence Submitted 
by the Company
The company conducted systematic literature reviews to 
identify relevant economic, cost and resource use, and 
health-related quality of life (HRQoL) evidence. None of 
the included cost-effectiveness studies were conducted from 
a UK perspective, and the company therefore built a de novo 
semi-Markov cohort state transition model. The model 
comprised three health states, i.e. progression-free (PF), 
progressed disease (PD) and death (Fig. 1). The company 
employed a semi-Markov approach, rather than a partitioned 
survival analysis approach, estimating PFS, time to progres-
sion (TTP) and post-progression survival (PPS), to inform 
transitions between health states [1, 3]. This avoided logical 
inconsistencies caused by the OS curve falling below the 
PFS curve.
The model adopted the perspective of the NHS and Per-
sonal Social Services. The model time horizon was 40 years, 
with a cycle length of 2 weeks in the first year and 4 weeks 
thereafter. A half-cycle correction was applied, but not to 
treatment and treatment administration costs. All costs and 
quality-adjusted life-years (QALYs) were discounted at a 
rate of 3.5% per year.
In line with its anticipated marketing authorisation, dur-
valumab was considered in the cost-effectiveness model for 
the treatment of locally advanced, unresectable, stage III 
NSCLC patients whose tumours express PD-L1 on ≥ 1% 
of TCs and whose disease has not progressed after two or 
more cycles of platinum-based CRT. This was a subgroup 
Fig. 1  Company’s model struc-
ture for locally advanced, unre-
sectable, stage III non-small 
cell lung cancer in adults whose 
tumours express programmed 
death-ligand 1 on ≥ 1% of 
tumour cells and whose dis-
ease has not progressed after 
platinum-based chemoradiation 
therapy
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from the final scope issued by NICE, which considered the 
same population regardless of their PD-L1 status. In line 
with the dosage used in the PACIFIC trial, durvalumab was 
modelled with a posology of 10 mg/kg administered as an 
intravenous infusion over 60 min every 2 weeks, until dis-
ease progression or unacceptable toxicity, or a maximum 
of 12 months. The comparator in the economic model was 
described as active follow-up or SoC, which applies up to 
disease progression. The company provided a more compre-
hensive definition of SoC in its response to the clarification 
letter, i.e. “surveillance every six months for two years with 
a visit including history, physical examination and—prefer-
ably contrast-enhanced—volume chest CT scan at least at 
12 and 24 months is recommended, and thereafter an annual 
visit including history, physical examination and chest CT 
scan in order to detect second primary tumours” [1].
The main source of evidence on treatment effectiveness 
used for intervention and comparators was the PACIFIC 
study [4]. Only data from the subgroup of PD-L1 ≥ 1% 
patients (according to the anticipated marketing authorisa-
tion) and from the March 2018 interim analysis data cut-off 
were used in the model. Parametric survival curves were 
fitted to patient-level data from PACIFIC on PFS, but instead 
of using the OS data from PACIFIC, the company per-
formed survival analyses on TTP and PPS. The probability 
of remaining in the PF state was estimated using PFS data 
by fitting independent parametric survival models. Based 
on statistical goodness of fit, the generalised gamma was 
selected to model PFS for both durvalumab and placebo. The 
PFS curve for durvalumab was altered to reflect a potential 
treatment waning effect caused by stopping treatment at a 
maximum of 12 months. From a chosen cut-off point, which 
was set to 10 years in the company’s base-case, an HR of 1 
was applied to the placebo curve to model durvalumab PFS.
Survival analysis of PFS data was used to determine the 
proportion of patients remaining in the progression-free 
health state. Instead of calculating the proportion of pro-
gressed patients based on OS and PFS, the probability of 
patients moving from PF to the PD health state was deter-
mined by survival analysis of TTP data (PFS data with 
deaths treated as censored) from PACIFIC. The probability 
of patients moving from PD to death was estimated using 
survival analysis of pooled PPS data from both treatment 
arms in PACIFIC (choice of exponential distribution based 
on best statistical fit). The effectiveness of subsequent treat-
ments was captured in the PPS to the extent that patients 
in PACIFIC received subsequent treatments. An alterna-
tive method for extrapolating PPS was used in a scenario 
analysis, where PPS was based on published data from 
the KEYNOTE-024 study, where data from the pembroli-
zumab arm was used for those patients in PACIFIC who 
received immuno-oncological (IO) treatment, and data from 
the chemotherapy arm was used for those not receiving IO 
treatment [5].
EQ-5D-5L data were collected in PACIFIC and mapped 
to 3L utility scores using the crosswalk mapping algorithm 
as per the NICE position statement [6]. A mixed-effects 
model with a covariate on progression status was used to 
estimate utility values for PF (0.810) and PD (0.776). No 
AE-related disutilities were taken into account.
Costs in the model included costs for PD-L1 testing, costs 
associated with treatment, disease management and patient 
observation, and costs associated with end-of-life care. Unit 
costs were based on the NHS reference costs [7], Personal 
Social Services Research Unit (PSSRU) [8], Monthly Index 
of Medical Specialities  (MIMS) [9], and the electronic 
Market Information Tool (eMIT) [10]. Treatment costs per 
durvalumab infusion were calculated based on the average 
body weight for patients in PACIFIC, with treatment dura-
tion taken from PACIFIC Kaplan–Meier (KM) data. The 
model assumed no drug wastage (i.e. perfect vial sharing) 
and zero acquisition and administration costs for SoC. Once 
patients progressed in the model, a one-off cost for subse-
quent treatments was accrued. This cost was informed by the 
type of treatment, the required treatment dose, the dosing 
schedule, the unit drug cost at list prices, and the duration of 
treatment. Resource use for the PF health state was modelled 
in accordance with European Society for Medical Oncol-
ogy (ESMO) guidelines [11], and resource use for PD was 
derived from NICE Technology Appraisal 531 in the meta-
static setting [12]. The frequency of occurrence of included 
AEs was combined with a one-off cost per AE to obtain a 
total per-cycle cost for each arm. All costs were inflated to 
the 2017 price level, if necessary.
In the company’s deterministic base-case analysis, 
total life-years (LYs) and QALYs gained, as well as total 
costs, were higher in the durvalumab arm compared with 
the SoC arm. Incremental QALYs were mainly driven by 
QALY gains in the PF health state, whereas incremental 
costs mainly resulted from higher treatment costs. After 
the company corrected a few errors and violations identi-
fied by the ERG, the deterministic (probabilistic, based on 
1000 iterations) incremental cost-effectiveness ratio (ICER) 
amounted to £19,366 (£21,601) per QALY gained. Some 
deterministic sensitivity analyses and scenario analyses sig-
nificantly affected the ICER, of which applying a 10-year 
time horizon and using a 3-year treatment waning cut-off 
were the most notable.
3.4  Critique of Cost‑Effectiveness Evidence 
and Interpretation
The CS and response to clarification provided sufficient 
detail for the ERG to appraise the literature searches and 
the 2018 update searches, which were deemed appropriate.
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The ERG had concerns about the model being based on 
post-hoc analyses: first, treatment effectiveness estimates 
were derived from a post-hoc subgroup analysis and sec-
ond, post-hoc TTP and PPS analyses were performed. Fur-
thermore, analyses were based on a population with mostly 
prior overlapping CRT instead of sequential CRT. Any bias 
introduced by these analyses remained unclear.
The ERG had concerns about the appropriateness of the 
semi-Markov approach and questioned its superiority over 
a partitioned survival model approach, given the imma-
turity of the survival data in the PACIFIC subpopulation. 
PPS data were naturally available for fewer patients than 
OS data, which meant that extrapolation from PPS drew on 
small sample sizes. Additional bias was potentially intro-
duced because data maturity had not been reached and the 
PPS analysis therefore relied on early progressors, with 
more progressions having occurred in the placebo arm than 
in the durvalumab arm (see also NICE Decision Support 
Unit [DSU], Technical Support Document [TSD] 19) [13]. 
Unfortunately, the company did not provide the partitioned 
survival analysis approach.
The main concern of the ERG in relation to the compa-
ny’s choice of PFS modelling (generalised gamma) was that 
it likely overestimated PFS, compared with PFS estimates 
observed in PACIFIC at 3 years. This model choice caused 
ICERs to be lower than with other model choices. It is note-
worthy that due to the PACIFIC estimate being based on 
small numbers of patients at risk (many censoring events), 
any choice for modelling PFS was associated with high lev-
els of uncertainty, and that different PFS model choices had 
a large impact on the ICERs. Alternative modelling meth-
ods, such as spline-based models, remained unexplored in 
the CS. The Gompertz distribution was used in a scenario 
analysis and the company did not explore the log-normal 
distribution, despite it making a better fit than the Gompertz 
distribution in both arms.
The ERG considered the choice of the 10-year time point 
for modelling treatment waning as highly uncertain, not 
appropriately validated, and potentially late, further add-
ing to the likely overestimation of durvalumab PFS. Fur-
thermore, setting the hazards for durvalumab and SoC to 
be equal after the chosen treatment duration cut-off in the 
company’s model could cause counter-intuitive results in 
some instances (with the ICER decreasing when the treat-
ment effect duration decreased). This was because the hazard 
of an event in the SoC arm could be lower than the hazard 
in the durvalumab arm when differential PFS distributions 
were chosen (so the earlier treatment effect cut-off lowered 
the hazard of progression in the durvalumab arm). The ERG 
considered that this method of modelling treatment waning 
was therefore inappropriate. However, alternative assump-
tions were also clinically implausible (e.g. a sudden drop in 
the number of patients not progressed or died). The ERG 
concluded that modelling treatment waning may introduce 
bias and that further research is necessary to establish good 
practices for modelling treatment waning, particularly when 
the intervention and comparator curves are modelled sepa-
rately. Ideally, longer-term data would be available to inform 
treatment effectiveness.
The ERG noted the uncertainty in PPS introduced by 
immature PPS data from PACIFIC, uncertainty about sub-
sequent treatments and potential bias in extrapolating PPS 
in the light of even smaller numbers of patients and imma-
ture data, compared with OS. Exploratory analyses showed 
that any impact of this on the ICER was probably rela-
tively small, with the main treatment benefit of durvalumab 
extending PFS.
AEs were modelled as a per-cycle occurrence while 
patients were receiving treatment. While AEs causally 
related to treatment were mostly higher for the durvalumab 
arm than in the placebo arm in PACIFIC, the incidence of 
AEs in the model between treatments was comparable. It 
was unclear how this discrepancy occurred, but it likely 
lowered the ICERs of durvalumab versus SoC; however, 
exploratory analyses showed that any bias caused by this 
was likely small.
The utility values for PF and PD derived from PACIFIC 
data were higher than in studies identified from the SR, 
which could potentially partly be explained by fewer patients 
in PACIFIC having metastatic disease than in the compara-
tor studies. However, utility values for both the PF and PD 
health states were comparable with those in the general 
population, which the ERG considered to be potentially an 
overestimate. Utility values were potentially overestimated 
and not adjusted by general population utility estimates. The 
high PF utility value produced lower ICERs, while the high 
PD utility value produced higher ICERs for durvalumab 
versus SoC. The ERG was also concerned that by excluding 
treatment as a factor in the mixed-effects model, and at the 
same time including disutilities of a limited set of AEs only 
in a sensitivity analysis, the true impact of treatment with 
durvalumab, as well as adverse events, was not appropriately 
captured in the model.
The ERG considered the assumption of perfect vial shar-
ing to be unrealistic in this setting, given the limited number 
of patients in England and Wales who would be eligible 
for treatment with durvalumab. This assumption caused the 
ICER of durvalumab against SoC to be lower compared 
with the ICER when the perfect vial sharing assumption 
was relaxed.
Compared with the company’s deterministic base-case 
results, probabilistic incremental QALYs were lower. Fur-
thermore, the company included patient characteristics in 
their PSA, and the 1000 iterations used in the PSA did not 
achieve stable results. Finally, the ERG was concerned about 
the external validation exercised by the company because 
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no firm conclusions could be drawn. The company stated 
that modelled OS broadly matched survival of the available 
sources, but this was a subjective observation. In addition, 
it was unclear whether the survival differences between the 
model and previous technology appraisals was caused by 
differences in population or by poor external validity of the 
current model.
3.5  Additional Work Undertaken by the ERG
Based on all considerations highlighted in the ERG critique, 
the ERG defined a new base-case in which various adjust-
ments were made to the company’s base-case. This included 
the correction of errors in the calculations of age and vial 
wastage of nivolumab and pembrolizumab as subsequent 
treatments and an error in the implementation of utility dec-
rements in the PSA, the application of a half-cycle correc-
tion to treatment and administration costs, the assumption of 
no vial sharing and the exclusion of patient characteristics 
from the PSA. As matters of judgement, the ERG used a dif-
ferent curve to extrapolate durvalumab PFS to avoid overes-
timation, selected a 5-year treatment waning cut-off, applied 
an age-related utility decrement, and included treatment as a 
covariate in the utility mixed-effects model. The ERG base-
case analysis resulted in larger deterministic (£50,238 per 
QALY gained) and probabilistic (£52,353 per QALY gained) 
ICERs than those in the company’s base-case.
Furthermore, the ERG explored alternative PFS distribu-
tions and treatment waning effects, the use of PPS based 
on PACIFIC and KEYNOTE-024, AEs incorporated with 
amended incidence and including the impact on HRQoL, 
alternative utility scores for the PF and PD states and the 
possibility of 30% vial sharing.
3.6  Conclusions of the ERG Report
Based on the PACIFIC data, there appears to be a benefit 
in both PFS and OS for durvalumab patients compared 
with placebo patients; however, the data are immature and 
there remains substantial uncertainty about the comparative 
effectiveness.
The ERG base-case ICER was estimated to be approxi-
mately £50,000 per QALY gained, but was subject to sub-
stantial uncertainty. The modelled long-term durvalumab 
PFS was highly uncertain given the model choice (gener-
alised gamma) that resulted in higher PFS estimates than 
observed in PACIFIC. There were concerns about the appro-
priateness of the semi-Markov approach given the imma-
turity of the survival data in PACIFIC, and the modelled 
population was narrower than that in the scope. Further 
uncertainties were related to the treatment effectiveness, 
potentially overestimated utility values, the assumption of 
perfect vial sharing, and discrepancies between AEs reported 
in PACIFIC and the AE incidence in the model. Some of 
these uncertainties were explored in scenario analyses and 
mostly further increased the ICER.
In conclusion, given that the ERG base-case ICER was 
estimated to be approximately £50,000 per QALY gained, 
with none of the scenarios resulting in ICERs below £30,000 
per QALY gained, and the large uncertainty induced by 
mainly the immature survival data, uncertainty around the 
cost effectiveness of durvalumab was substantial.
4  Key Methodological Issues
The chosen parametric model to estimate PFS (generalised 
gamma) in this appraisal likely overestimated durvalumab 
PFS in PACIFIC. NICE DSU TSD 14 recommends the use 
of the same type of parametric model for individual treat-
ment arms to avoid drastically different shapes of survival 
curves, unless there is justification for deviating from this 
guidance: “using clinical expert judgement, biological plau-
sibility, and robust statistical analysis” [14]. As detailed 
above, there were reasons to believe that differential curves 
to model PFS for durvalumab (log-normal) and SoC (gen-
eralised gamma) exhibited superior external validity and 
plausibility. Given that the number of cancer treatments 
with potential for cure is expected to increase, the need for 
guidance and best practices on when to choose differential 
survival curves per treatment arm may increase in parallel.
The implementation of the treatment waning effect, set-
ting the HR to 1 at the chosen cut-off, can cause counter-
intuitive results when the per-period hazard in the compara-
tor arm is below that of the hazard in the intervention arm, 
which can happen, for example, when differential survival 
models are chosen. This can occur depending on the chosen 
cut-off and when rates of progression or dying in the begin-
ning periods are high in the comparator arm, such that the 
few remaining patients alive and not progressed in later peri-
ods then have very low rates of progression or dying. A haz-
ard cap was proposed by the company to solve this issue but 
this was not based on clinical evidence or validated methods. 
The ERG does not consider it entirely clinically implausible 
that, at some point, the proportion of patients progressed 
would be higher in the durvalumab arm than in the SoC 
arm. This could, for example, be a plausible scenario where 
a treatment delays progression but does not avert it more 
effectively than SoC. A hazard cap should therefore not be 
employed without being based on clinical evidence. The 
ERG therefore considers the method for implementing treat-
ment waning to be flawed, but acknowledges that there is a 
lack of guidance related to alternative modelling methods 
and appropriate assumptions. With many appraisals cur-
rently considering treatment waning (given the uncertainty 
about long-term treatment effectiveness), this is a pressing 
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issue. Modelling treatment waning may introduce bias and 
further research is necessary to establish good practices for 
its modelling.
The approach of modelling PPS instead of OS may intro-
duce bias. Survival data in PACIFIC are immature, and, 
although this issue persists regardless of model choice (OS 
or PPS), modelling PPS instead of OS is necessarily based 
on smaller sample sizes used for long-term extrapolation, 
thereby exacerbating uncertainty. Furthermore, the PPS 
analysis was potentially biased because groups were no 
longer balanced. Early progressors may have a different 
survival time than patients with later progression [13]. In 
addition, the PPS was estimated using both treatment and 
comparator groups together, but PPS data included more 
patients treated with placebo (who progressed earlier), 
potentially introducing additional bias. Alternative standard 
OS analysis should be provided in addition to exploring any 
bias stemming from this choice of analysis and assessing 
the potential impact.
5  National Institute for Health and Care 
Excellence Guidance
On 14 February 2019, NICE recommended durvalumab 
monotherapy for use within the Cancer Drugs Fund (CDF) 
as an option for treating locally advanced unresectable 
NSCLC in adults whose tumours express PD-L1 on ≥ 1% 
of tumour cells and whose disease has not progressed after 
platinum-based chemoradiation therapy, only if platinum-
based chemoradiation was administered concurrently and the 
conditions in the managed access agreement for durvalumab 
are followed.
5.1  Consideration of Clinical Effectiveness
The NICE technical report considered the difference between 
types of prior CRT that could affect the generalisability of 
trial results and clinical practice in the NHS [1]. However, 
it stated that PACIFIC remains the best available source of 
evidence for this appraisal and that, based on clinical expert 
advice, the difference in outcomes between overlapping and 
sequential CRT is likely to be small.
The report also considered the suggestion of the CS that 
durvalumab meets the end-of-life criteria specified by NICE 
[1, 15]. It concluded that the criteria were not met due to 
the index population not meeting the short life expectancy 
criterion.
The report also considers the submission being based on 
a more restricted population than the NICE scope to be “a 
substantial area of uncertainty in the appraisal”.
5.2  Consideration of Cost Effectiveness
The AC considered that assuming a 3- to 5-year treatment 
effect duration is plausible but concluded that the long-
term treatment effect of durvalumab after stopping treat-
ment was highly uncertain when considering the input from 
clinical experts. The AC agreed that the immature PFS data 
from PACIFIC, and the small numbers at the end of the 
KM curve, introduced uncertainty in all extrapolations and 
therefore concluded that more mature PFS data are needed 
to inform long-term model predictions. The AC accepted a 
hazard cap that was proposed by the company to prevent the 
risk of progression in the durvalumab arm exceeding the risk 
in the standard care arm when using the log-normal and gen-
eralised gamma distributions. The AC concluded that it was 
acceptable to use the PFS utility value from PACIFIC for the 
PF health state, and, for consistency in the economic model, 
the use of the PD utility from PACIFIC for the PD health 
state was also considered appropriate. The AC also con-
sidered that using a treatment-related decrement to model 
adverse events was appropriate, but this decrement would 
not apply indefinitely. Finally, the AC concluded that the 
most plausible ICERs for durvalumab are uncertain and are 
not clearly within the range considered to be cost effective.
6  Conclusions
As detailed previously, there is substantial uncertainty 
regarding the effectiveness results that come from an 
interim analysis conducted in a restricted population. Fur-
thermore, the generalisability of the results to UK clinical 
practice might be limited as only eight patients in the UK 
were included and there were differences between types of 
prior CRT.
The Committee did not recommend durvalumab for 
standard use in the NHS, but did recommend it within the 
CDF for a subpopulation (concurrent platinum-based chem-
oradiation therapy) with a commercially managed access 
agreement in place. This recommendation was made as the 
evidence from the only available trial was not generalisable 
to the whole UK population (which mainly receives sequen-
tial platinum-based chemoradiation therapy, not studied in 
the trial), the data from the trial were immature, and the trial 
was still ongoing. In particular, the committee was inter-
ested in further evidence on how long the treatment effect of 
durvalumab lasts, and how many people taking durvalumab 
would live without their disease progressing (‘cure’), on 
both of which further information is being collected in the 
ongoing trial. The recommendation within the CDF may 
be perceived as problematic given that the most plausible 
ICERs were above the range considered to be cost effec-
tive by NICE. Furthermore, in order to guarantee the value 
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of data collection within the CDF, this should be formally 
assessed. Reimbursement within the CDF should be consid-
ered carefully, potentially with the addition of further condi-
tions on data to be collected and/or reimbursed.
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